Osimertinib Mesylate Patent Expiration
Osimertinib Mesylate is Used for treating locally advanced or metastatic non-small cell lung cancer with specific mutations in combination with chemotherapy. It was first introduced by Astrazeneca Pharmaceuticals Lp
Osimertinib Mesylate Patents
Given below is the list of patents protecting Osimertinib Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tagrisso | US10183020 | Pharmaceutical compositions comprising AZD9291 | Jan 02, 2035 | Astrazeneca |
| Tagrisso | US8946235 | 2-(2,4,5-substituted-anilino) pyrimidine compounds | Aug 08, 2032 | Astrazeneca |
| Tagrisso | US11524951 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | Jul 25, 2032 | Astrazeneca |
| Tagrisso | US9732058 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | Jul 25, 2032 | Astrazeneca |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Osimertinib Mesylate's patents.
Latest Legal Activities on Osimertinib Mesylate's Patents
Given below is the list recent legal activities going on the following patents of Osimertinib Mesylate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation Critical | 13 Dec, 2022 | US11524951 |
| Recordation of Patent Grant Mailed Critical | 13 Dec, 2022 | US11524951 |
| Email Notification Critical | 23 Nov, 2022 | US11524951 |
| Issue Notification Mailed Critical | 22 Nov, 2022 | US11524951 |
| Application Is Considered Ready for Issue Critical | 31 Oct, 2022 | US11524951 |
| Dispatch to FDC | 31 Oct, 2022 | US11524951 |
| Issue Fee Payment Received Critical | 28 Oct, 2022 | US11524951 |
| Issue Fee Payment Verified Critical | 28 Oct, 2022 | US11524951 |
| Electronic Review Critical | 21 Oct, 2022 | US11524951 |
| Mail Response to 312 Amendment (PTO-271) Critical | 20 Oct, 2022 | US11524951 |
Osimertinib Mesylate's Family Patents
